Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-291 phase 3 trial of capivasertib + fulvestrant versus placebo + fulvestrant in HR-positive, HER2-negative advanced breast cancer
MOH_2020-02-02_008670Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Capivasertib + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoints: Efficacy and Safety. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
capivasertibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-02-02_008670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-02_008670.